368 related articles for article (PubMed ID: 20960568)
1. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability.
Goldberg DS; Bishop SM; Shah AU; Sathish HA
J Pharm Sci; 2011 Apr; 100(4):1306-15. PubMed ID: 20960568
[TBL] [Abstract][Full Text] [Related]
2. High-throughput screening of formulations to optimize the thermal stability of a therapeutic monoclonal antibody.
Niedziela-Majka A; Kan E; Weissburg P; Mehra U; Sellers S; Sakowicz R
J Biomol Screen; 2015 Apr; 20(4):552-9. PubMed ID: 25385011
[TBL] [Abstract][Full Text] [Related]
3. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies.
Brader ML; Estey T; Bai S; Alston RW; Lucas KK; Lantz S; Landsman P; Maloney KM
Mol Pharm; 2015 Apr; 12(4):1005-17. PubMed ID: 25687223
[TBL] [Abstract][Full Text] [Related]
4. DSF method optimization and its application in predicting protein thermal aggregation kinetics.
Shi S; Semple A; Cheung J; Shameem M
J Pharm Sci; 2013 Aug; 102(8):2471-83. PubMed ID: 23754479
[TBL] [Abstract][Full Text] [Related]
5. Utility of High Throughput Screening Techniques to Predict Stability of Monoclonal Antibody Formulations During Early Stage Development.
Goldberg DS; Lewus RA; Esfandiary R; Farkas DC; Mody N; Day KJ; Mallik P; Tracka MB; Sealey SK; Samra HS
J Pharm Sci; 2017 Aug; 106(8):1971-1977. PubMed ID: 28456733
[TBL] [Abstract][Full Text] [Related]
6. High throughput thermostability screening of monoclonal antibody formulations.
He F; Hogan S; Latypov RF; Narhi LO; Razinkov VI
J Pharm Sci; 2010 Apr; 99(4):1707-20. PubMed ID: 19780136
[TBL] [Abstract][Full Text] [Related]
7. High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies.
Li Y; Mach H; Blue JT
J Pharm Sci; 2011 Jun; 100(6):2120-35. PubMed ID: 21491438
[TBL] [Abstract][Full Text] [Related]
8. Application of a high-throughput relative chemical stability assay to screen therapeutic protein formulations by assessment of conformational stability and correlation to aggregation propensity.
Rizzo JM; Shi S; Li Y; Semple A; Esposito JJ; Yu S; Richardson D; Antochshuk V; Shameem M
J Pharm Sci; 2015 May; 104(5):1632-40. PubMed ID: 25757872
[TBL] [Abstract][Full Text] [Related]
9. High Throughput Differential Scanning Fluorimetry (DSF) Formulation Screening with Complementary Dyes to Assess Protein Unfolding and Aggregation in Presence of Surfactants.
McClure SM; Ahl PL; Blue JT
Pharm Res; 2018 Mar; 35(4):81. PubMed ID: 29508082
[TBL] [Abstract][Full Text] [Related]
10. Temperature-ramped studies on the aggregation, unfolding, and interaction of a therapeutic monoclonal antibody.
Menzen T; Friess W
J Pharm Sci; 2014 Feb; 103(2):445-55. PubMed ID: 24382634
[TBL] [Abstract][Full Text] [Related]
11. Thermodynamic Unfolding and Aggregation Fingerprints of Monoclonal Antibodies Using Thermal Profiling.
Melien R; Garidel P; Hinderberger D; Blech M
Pharm Res; 2020 Apr; 37(4):78. PubMed ID: 32236701
[TBL] [Abstract][Full Text] [Related]
12. Orthogonal Methods for Characterizing the Unfolding of Therapeutic Monoclonal Antibodies: Differential Scanning Calorimetry, Isothermal Chemical Denaturation, and Intrinsic Fluorescence with Concomitant Static Light Scattering.
Temel DB; Landsman P; Brader ML
Methods Enzymol; 2016; 567():359-89. PubMed ID: 26794361
[TBL] [Abstract][Full Text] [Related]
13. A comparison of biophysical characterization techniques in predicting monoclonal antibody stability.
Thiagarajan G; Semple A; James JK; Cheung JK; Shameem M
MAbs; 2016; 8(6):1088-97. PubMed ID: 27210456
[TBL] [Abstract][Full Text] [Related]
14. High Throughput Prediction Approach for Monoclonal Antibody Aggregation at High Concentration.
Zidar M; Šušterič A; Ravnik M; Kuzman D
Pharm Res; 2017 Sep; 34(9):1831-1839. PubMed ID: 28593474
[TBL] [Abstract][Full Text] [Related]
15. Nonnative aggregation of an IgG1 antibody in acidic conditions: part 1. Unfolding, colloidal interactions, and formation of high-molecular-weight aggregates.
Brummitt RK; Nesta DP; Chang L; Chase SF; Laue TM; Roberts CJ
J Pharm Sci; 2011 Jun; 100(6):2087-103. PubMed ID: 21213308
[TBL] [Abstract][Full Text] [Related]
16. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
[TBL] [Abstract][Full Text] [Related]
17. Isothermal chemical denaturation as a complementary tool to overcome limitations of thermal differential scanning fluorimetry in predicting physical stability of protein formulations.
Svilenov H; Markoja U; Winter G
Eur J Pharm Biopharm; 2018 Apr; 125():106-113. PubMed ID: 29329817
[TBL] [Abstract][Full Text] [Related]
18. Probing Thermal Stability of Proteins with Temperature Scanning Viscometer.
Jiang B; Jain A; Lu Y; Hoag SW
Mol Pharm; 2019 Aug; 16(8):3687-3693. PubMed ID: 31306023
[TBL] [Abstract][Full Text] [Related]
19. High throughput methods of assessing protein stability and aggregation.
Senisterra GA; Finerty PJ
Mol Biosyst; 2009 Mar; 5(3):217-23. PubMed ID: 19225610
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous High-Throughput Conformational and Colloidal Stability Screening Using a Fluorescent Molecular Rotor Dye, 4-(4-(Dimethylamino)styryl)-N-Methylpyridinium Iodide (DASPMI).
Wong JJ; Wright SK; Ghozalli I; Mehra R; Furuya K; Katayama DS
J Biomol Screen; 2016 Sep; 21(8):842-50. PubMed ID: 27138878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
